Subungual Melanoma: A Single Institution Experience.
Christopher J LaRoccaLily LaiRebecca A NelsonBadri ModiBrooke CrawfordPublished in: Medical sciences (Basel, Switzerland) (2021)
Despite the changing paradigms of melanoma treatment in recent years, there remains a relative paucity of data regarding subungual melanoma in the literature. From 2002-2018, 25 patients with subungual melanoma were surgically treated at our facility. A retrospective chart review was conducted to collect relevant demographic, clinical, pathologic, and outcomes data. The median age at diagnosis was 69 years. Most patients (60%) were male, and the melanoma lesion was most often located on the foot (68%). Acral-lentiginous was the most common histologic subtype (59%), and the median Breslow thickness was 3.4 mm. Fifteen patients (63%) underwent a sentinel lymph node biopsy as part of their surgical resection, and four of these patients (27%) had metastatic disease in the lymph nodes. In total, 10 patients underwent lymph node dissection of the involved basin. The median follow up was 21 months in this patient population. Age, gender, tumor location, ulceration, and lesion histology were not significantly associated with recurrence free survival (RFS). Increasing Breslow thickness was found to be significantly associated with shorter RFS (HR: 1.07, CI: 1.03-1.55). In total, 13 patients developed a disease recurrence, and RFS rates were 66% at 1 year and 40% at 3 years. Additionally, 91 and 37% of patients were alive at one year and three years, respectively. Subungual melanomas are rare lesions that often have a more advanced stage at diagnosis, which contributes to the poor prognosis of these cutaneous malignancies.
Keyphrases
- end stage renal disease
- newly diagnosed
- lymph node
- chronic kidney disease
- prognostic factors
- sentinel lymph node
- peritoneal dialysis
- type diabetes
- systematic review
- early stage
- adipose tissue
- patient reported outcomes
- free survival
- insulin resistance
- machine learning
- case report
- climate change
- minimally invasive
- skin cancer